Most people missed it. A study just showed something absolutely wild: A single CRISPR infusion cut people’s cholesterol and triglycerides in half. Yes - half. From one treatment. And if this holds up? Heart disease may never look the same again. Let me explain: The target was a gene called ANGPTL3 — a tiny switch in your liver that controls how much LDL (“bad” cholesterol) and triglycerides float in your blood. Some people are born with this gene naturally turned off. They live their whole lives with ultra-low lipids. And they almost never get heart disease. Nature gave us the blueprint. So researchers did something bold: They used CRISPR–Cas9 to recreate that natural mutation. Not a pill. Not an injection every 2 weeks. Not a lifetime of medication. Just one IV infusion designed to permanently switch off ANGPTL3. The results? In the highest-dose group: LDL dropped ~50% Triglycerides dropped ~55% After just 60 days From a single treatment. Let that sink in. This isn’t controlling cholesterol. It’s rewiring the biology that creates it. And yes - this all happened in humans. Not mice. Not petri dishes. Not hype. 15 real patients with severe lipid disorders got the therapy. Is it early? Extremely. But it’s the strongest signal so far that gene editing can target a common disease - not just rare ones. Why does this matter? Because cardiovascular disease is still the world’s #1 killer. We already have statins, PCSK9 inhibitors, lifestyle programs… But millions still can’t reach safe levels, can’t tolerate drugs, or can’t sustain lifelong treatment. A “one-and-done” therapy changes the entire game. Even the clinicians were stunned. “We can move from chronic therapy to something that’s one-and-done.” - Luke Laffin, Cleveland Clinic Imagine telling a patient: “You’ll never need cholesterol medication again.” That’s the scale of what’s being tested here. But here’s the catch - and it’s a big one: This is very early science. 15 people treated. Only ~2 months of data. Long-term risks unknown. CRISPR editing inside the body. Off-target effects must be monitored. Large trials will require thousands of participants No honest scientist will promise miracles yet. The real shift is this: For the first time, gene editing isn’t just for rare disorders. It’s stepping into the diseases that kill millions. Ten years ago, investors told researchers this would never happen. Too risky. Too expensive. Too ambitious. Now? Dozens of companies are racing to bring CRISPR to heart disease. The field flipped. The future is suddenly visible: CRISPR for high blood pressure. CRISPR for metabolic diseases. CRISPR for common cancers. CRISPR for high cholesterol. CRISPR for heart failure. CRISPR for diabetes. We’re watching the beginning of gene editing as mainstream medicine. Not science fiction. Science translation. If the safety data holds… If the lipid reductions are durable… If the therapy becomes affordable… Then the world’s #1 killer - heart disease - might finally meet a challenger stronger than any pill. And it started with 15 volunteers and one gene. That’s the story: CRISPR isn’t just fixing rare diseases anymore. It’s coming for the diseases almost everyone has. The next decade of medicine is going to look nothing like the last.